- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01283698
Clinical Trial to Investigate Efficacy of LAS41004 in Psoriasis
An Investigator-blind, Controlled Study to Assess the Efficacy of Distinct Combinations of LAS 41004 in Different Concentrations Compared to Placebo and to Active Control in a Psoriasis-Plaque-Test
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Mahlow, Germany
- Almirall Investigational Sites#1
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
• Male or female patients between 18 and 75 years of age with a diagnosis of stable plaque-type psoriasis (psoriasis vulgaris) for at least 6 month
Psoriasis plaques that are suitable to be defined as target area lesions by the following criteria:
- Psoriasis plaques must be located at trunk and/or extremities. Plaques that are located on the head (incl. scalp), palms, sole of the feet, intertriginous or genitoanal areas are not suitable as target areas
- Comparable psoriasis plaques with at least "2" in each score (Range 0-4) for the three distinct symptoms scaling; erythema; and induration
- No more than 3 points difference in total score (= sum of scores for scaling, erythema and induration; Range 0-12) of the chosen comparable psoriasis plaques
- Enough psoriatic surface area to define 5 clearly distinguishable (minimum distance between test areas: 1cm) test areas of at least 1 cm² plaque size
- Patient is willing and able to comply with the requirements of the clinical study protocol. In particular, patient must adhere SCIderm GmbH Confidential Almirall Hermal GmbH Study protocol EudraCT No. 2010-022281-27 Protocol No. H553000-1005 Version 1.0 to concomitant therapy prohibitions of the test areas and must agree to avoid intense UV exposure of the test areas during the study
- Written informed consent to participate in the study, prior to any study related procedures, indicating an understanding of the purpose of the study
A patient of childbearing potential agrees to use one of the following contraceptive methods for the duration of the study and the following 4 weeks after the end of study :
- Strict abstinence (exception: male partner with a vasectomy for at least 3 months prior to study entry is allowed)
- Combined oral, implanted or injectable contraceptives on a stable dose for at least 3 months prior to study entrance
- Intrauterine device (IUD) inserted for at least 1 month prior to study entrance
Exclusion Criteria:
- Too few body surface area covered with psoriasis plaques that meet the specified inclusion criteria to be defined as 5 clearly distinguishable test areas
- Any condition that may interfere with the study assessments or sonographic measurements of the skin and/or may have an influence on skin immune response (incl. open wounds)
- Known adverse reactions of any severity or hypersensitivity to any ingredient of the test products
- No willingness to avoid induction of heavy sweating, e.g. due to sauna visits, excessive sports activities during the study course
- No willingness to avoid swimming, bathing or wetting of the designated test areas between visits
- Pregnant or breast-feeding women
- A medical condition that may put the patient at a general risk and therefore would prevent participation in the clinical trial (including but not limited to: serious infectious diseases, major surgery within the last 4 weeks, coronary artery disease, renal impairment, hepatic impairment, uncontrolled metabolic diseases, disorders of the calcium metabolism, autoimmune diseases)
- History or presence of malignant disease (other than surgically removed basal cell carcinoma) and/or auto immune diseases
- Current diagnosis of guttate, erythrodermic or pustular psoriasis
- Patients who did not respect the following wash-out periods prior or during the study:
Treatment Wash out period Topical treatment in the test area Any topical anti-psoriatic drug 2 weeks Systemic treatment Biologics 6 months Any other systemic treatment (corticosteroids, ciclosporin, MTX, fumaric acid esters) 3 months Procedures Phototherapy 4 weeks
- Significant skin diseases other than plaque-type psoriasis (psoriasis vulgaris), incl. skin infections
- Excessive sunlight exposure within 28 days prior to study entry and during the conduct of the study
- Usage of any topical formulation (incl. cosmetics, emollients, etc) on the designated target areas during the course of the study
- Vaccination 6 days prior to enrolment or during the study
- Subjects who are - in the opinion of the investigator - unreliable, and/or non-compliant, and/or who present with any condition or treatment (including cosmetic products) that may interfere with psoriasis or the conduct of the trial
- Participation in any other clinical trial within 30 days prior or during this trial
- Subject is an adult under guardianship, hospitalised, deprived of freedom or unable to communicate or cooperate with the investigator due to language or mental problems
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LAS 41004 dosage 1
dosage 1, once daily
|
dosage 1, once daily
|
Experimental: LAS 41004 dosage 2
dosage 2, once daily
|
LAS 41004 dosage 2, once daily
|
Experimental: LAS 41004 dosage 3
dosage 3, once daily
|
dosage 3, once daily
|
Placebo Comparator: placebo
once daily
|
once daily
|
Active Comparator: Reference
once daily
|
Active Comparator,once daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decrease in thickness of infiltration
Time Frame: 15 days
|
measurement will be performed by ultrasound, comparing data from baseline (day1) vs end of trial (day15)
|
15 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in clinical score
Time Frame: 15 days
|
scoring will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15)
|
15 days
|
Change in erythema score
Time Frame: 15 days
|
scoring will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15)
|
15 days
|
Change in Induration score
Time Frame: 15 days
|
scoring will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15)
|
15 days
|
Change in Scaling score
Time Frame: 15 days
|
scoring will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15)
|
15 days
|
Number of skin reactions per patient as a measure of safety and tolerability
Time Frame: 15 days
|
daily scoring will be performed by investigator
|
15 days
|
Number of AEs per patients as a measure of safety and tolerability
Time Frame: 15 days
|
reporting will be performed by investigator
|
15 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H553000-1005
- 2010-022281-27 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingGeneralized Pustular Psoriasis (GPP)China
Clinical Trials on Experimental: LAS 41004 dosage 1
-
Almirall, S.A.Completed
-
Wake Forest University Health SciencesMichael J. Fox Foundation for Parkinson's ResearchWithdrawn
-
Jun ZhangXiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...Active, not recruiting
-
Virginia Commonwealth UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedChronic Low Back Pain | Fear of Pain | Fear of InjuryUnited States
-
Duke UniversityStanford University; Department for International Development, United Kingdom; International Initiative for Impact Evaluation and other collaboratorsCompletedSepsis | Obstetric Labor Complications | Pre-eclampsia | Neonatal Mortality | Post-partum HemorrhageIndia
-
Istanbul University - Cerrahpasa (IUC)Completed
-
Assistance Publique - Hôpitaux de ParisMedtronic - MITG; Kimberly-Clark CorporationCompletedMechanical Ventilation Complication | Acute Respiratory FailureFrance
-
Trinomab Biotech Co., Ltd.TIGERMED AUSTRALIA PTY LIMITEDCompletedHealthy Adult SubjectsAustralia
-
University Hospital, ToulouseCentre National de la Recherche Scientifique, FranceRecruitingAttention Deficit | Hyperactivity DisorderFrance
-
Brigham and Women's HospitalUniversity of Pennsylvania; Breast Cancer Research Foundation; Ministry of Health... and other collaboratorsCompleted